These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 30583086

  • 1. Procalcitonin levels predicting the infliximab response of immunoglobulin resistant Kawasaki disease.
    Nakashima Y, Nanishi E, Yamamura K, Uike K, Terashi E, Hirata Y, Nagata H, Morihana E, Tanaka T, Honjo S, Takada H, Ohga S.
    Cytokine; 2019 Feb; 114():26-31. PubMed ID: 30583086
    [Abstract] [Full Text] [Related]

  • 2. Serum amyloid A as a biomarker for immunoglobulin resistance in Kawasaki disease.
    Huang XB, Zhao S, Liu ZY, Xu YY, Deng F.
    Ann Med; 2023 Feb; 55(2):2264315. PubMed ID: 37870383
    [Abstract] [Full Text] [Related]

  • 3. Predictive value of serum procalcitonin for both initial and repeated immunoglobulin resistance in Kawasaki disease: a prospective cohort study.
    Shao S, Luo C, Zhou K, Hua Y, Wu M, Liu L, Liu X, Wang C.
    Pediatr Rheumatol Online J; 2019 Nov 27; 17(1):78. PubMed ID: 31775782
    [Abstract] [Full Text] [Related]

  • 4. Procalcitonin as a Biomarker of Unresponsiveness to Intravenous Immunoglobulin for Kawasaki Disease.
    Nakamura N, Muto T, Masuda Y, Numoto S, Kodama S, Miyamoto R, Miyata K, Hayakawa T, Mori H, Kuroyanagi Y, Akaihata M, Iwayama H, Kurahashi H, Shimomura Y, Nagai T, Hori T, Agata H, Okumura A.
    Pediatr Infect Dis J; 2020 Sep 27; 39(9):857-861. PubMed ID: 32433223
    [Abstract] [Full Text] [Related]

  • 5. Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients.
    Sato S, Kawashima H, Kashiwagi Y, Hoshika A.
    Int J Rheum Dis; 2013 Apr 27; 16(2):168-72. PubMed ID: 23773640
    [Abstract] [Full Text] [Related]

  • 6. Analysis of biomarker serum levels in IVIG and infliximab refractory Kawasaki disease patients.
    Hachiya A, Kobayashi N, Matsuzaki S, Takeuchi Y, Akazawa Y, Shigemura T, Motoki N, Masumoto J, Agematsu K.
    Clin Rheumatol; 2018 Jul 27; 37(7):1937-1943. PubMed ID: 29302828
    [Abstract] [Full Text] [Related]

  • 7. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
    Burns JC, Roberts SC, Tremoulet AH, He F, Printz BF, Ashouri N, Jain SS, Michalik DE, Sharma K, Truong DT, Wood JB, Kim KK, Jain S, KIDCARE Multicenter Study Group.
    Lancet Child Adolesc Health; 2021 Dec 27; 5(12):852-861. PubMed ID: 34715057
    [Abstract] [Full Text] [Related]

  • 8. Prediction of repeated intravenous immunoglobulin resistance in children with Kawasaki disease.
    Lu Y, Chen T, Wen Y, Si F, Wu X, Yang Y.
    BMC Pediatr; 2021 Sep 16; 21(1):406. PubMed ID: 34530763
    [Abstract] [Full Text] [Related]

  • 9. Do cytokines correlate with refractory Kawasaki disease in children?
    Wang Y, Qian SY, Yuan Y, Wang Q, Gao L, Chen X, Yu X, Zhen Z.
    Clin Chim Acta; 2020 Jul 16; 506():222-227. PubMed ID: 32156603
    [Abstract] [Full Text] [Related]

  • 10. Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis.
    Li X, Tang Y, Ding Y, Chen Y, Hou M, Sun L, Qian G, Qin L, Lv H.
    Eur J Pharmacol; 2021 May 15; 899():173985. PubMed ID: 33652059
    [Abstract] [Full Text] [Related]

  • 11. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
    Jone PN, Anderson MS, Mulvahill MJ, Heizer H, Glodé MP, Dominguez SR.
    Pediatr Infect Dis J; 2018 Oct 15; 37(10):976-980. PubMed ID: 29461447
    [Abstract] [Full Text] [Related]

  • 12. TNF-α is superior to conventional inflammatory mediators in forecasting IVIG nonresponse and coronary arteritis in Chinese children with Kawasaki disease.
    Hu P, Jiang GM, Wu Y, Huang BY, Liu SY, Zhang DD, Xu Y, Wu YF, Xia X, Wei W, Hu B.
    Clin Chim Acta; 2017 Aug 15; 471():76-80. PubMed ID: 28526535
    [Abstract] [Full Text] [Related]

  • 13. Prediction of intravenous immunoglobulin resistance in Kawasaki disease in children.
    Wu S, Liao Y, Sun Y, Zhang CY, Zhang QY, Yan H, Qi JG, Liu XQ, Chen YH, Wang YL, Li XY, Jin HF, Du JB.
    World J Pediatr; 2020 Dec 15; 16(6):607-613. PubMed ID: 32232677
    [Abstract] [Full Text] [Related]

  • 14. [Values of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in predicting sensitivity to intravenous immunoglobulin in Kawasaki disease].
    Yuan YD, Sun J, Li PF, Wei CL, Yu YH.
    Zhongguo Dang Dai Er Ke Za Zhi; 2017 Apr 15; 19(4):410-413. PubMed ID: 28407827
    [Abstract] [Full Text] [Related]

  • 15. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.
    Roberts SC, Jain S, Tremoulet AH, Kim KK, Burns JC, KIDCARE Multicenter Study Group, Anand V, Anderson M, Ang J, Ansusinha E, Arditi M, Ashouri N, Bartlett A, Chatterjee A, DeBiasi R, Dekker C, DeZure C, Didion L, Dominguez S, El Feghaly R, Erdem G, Halasa N, Harahsheh A, Jackson MA, Jaggi P, Jain S, Jone PN, Kaushik N, Kurio G, Lillian A, Lloyd D, Manaloor J, McNelis A, Michalik DE, Newburger J, Newcomer C, Perkins T, Portman M, Romero J, Ronis T, Rowley A, Schneider K, Schuster J, Tejtel SKS, Sharma K, Simonsen K, Szmuszkovicz J, Truong D, Wood J, Yeh S.
    Contemp Clin Trials; 2019 Apr 15; 79():98-103. PubMed ID: 30840903
    [Abstract] [Full Text] [Related]

  • 16. [Expression of interleukin-17A in serum of children with intravenous immunoglobulin-resistant Kawasaki disease and its clinical significance].
    Li SY, Ding Y.
    Zhongguo Dang Dai Er Ke Za Zhi; 2023 Mar 15; 25(3):244-249. PubMed ID: 36946157
    [Abstract] [Full Text] [Related]

  • 17. Indicators of unresponsiveness after initial i.v. immunoglobulin treatment in acute Kawasaki disease.
    Hashimoto I.
    Pediatr Int; 2019 Jul 15; 61(7):641-646. PubMed ID: 31132210
    [Abstract] [Full Text] [Related]

  • 18. Infliximab as the First Retreatment in Patients with Kawasaki Disease Resistant to Initial Intravenous Immunoglobulin.
    Youn Y, Kim J, Hong YM, Sohn S.
    Pediatr Infect Dis J; 2016 Apr 15; 35(4):457-9. PubMed ID: 26673981
    [Abstract] [Full Text] [Related]

  • 19. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.
    Han CL, Zhao SL.
    Med Sci Monit; 2018 Oct 11; 24():7264-7270. PubMed ID: 30307902
    [Abstract] [Full Text] [Related]

  • 20. Predictive value of albumin for intravenous immunoglobulin resistance in a large cohort of Kawasaki disease patients.
    Zhang R, Shuai S, Zhang H, Cai J, Cui N, Tang M, Xing S, Gao Y, Liu X, Yang X.
    Ital J Pediatr; 2023 Jun 25; 49(1):78. PubMed ID: 37357258
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.